October 2020 Issue Table Of Contents

From The Editor

• Will The Pandemic Be The Actual Death Of Print?

Feature Articles

• David Lucchino’s Circuitous Route To CEO Of Frequency Therapeutics

Capitol Perspectives

• Democratic And Republican Health Priorities In The Next Administration

CEO Corner

• Hiring C-Suite Leadership During The Pandemic
• How The Right Culture Leads To Highly Productive Teams

Companies To Watch

• Osivax

From Policy to Execution

• Trust In Institutional Practices Keep Pandemics From Becoming Pandemonium

Patient Perspectives

• Changing How We Target Rare Diseases

Industry Research

• PPA Differences Between Small And Large Sponsors

Inside The Industry

• Why COGs Will Demand More Attention From Biosimilar Makers
• Changing The Status Quo Regarding Diversity In Clinical Trials
• COVID Revs Up The Antibiotics Space
• Using McKinsey’s 7-S Framework To Achieve Quality Culture
• Women In Bio Riding The Waves Of Change
• What Makes Outsourcers Very Satisfied?

Leadership Lessons

• Right Now, You Should Think “Coach First”

Ask The Board

• What — If Any — Silver Linings Have You Observed Taking Place At Your Company Resulting From The Chaos Caused By COVID-19?
• What’s Your Perspective On The Rise Around Virtual Pitching To Investors, And What Will Be Its Impact On Annual Investor Meetings Like The Biotech Showcase And JPM In 2021?
• What Is Your Biggest Concern Regarding The Biopharma Industry’s Reputation With The American People If We Don’t Have A COVID-19 Vaccine By The End Of This Year?